课题基金 / 基金详情

The mechanism of phiC31 integrase; a unidirectional recombinase for genome engineering

The mechanism of phiC31 integrase; a unidirectional recombinase for genome engineering
phiC31整合酶的机制;
批准号:
BB/H001212/1
负责人:
Margaret Smith
金额:
$52.63万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2009
资助国家:
英国
项目状态:
已结题
起止时间:
2009 至 --

项目摘要

项目成果

Margaret Smith的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
It is really difficult to cure people with genetic diseases. These diseases are caused by defective genes. The best cure would be to give them a gene that works. Ideally this treatment would need to be given only once in their lifetime because genes, when they are part of the chromosome, are passed faithfully from one cell to the next and so the cure would perpetuate. Although this sounds simple, in practice its very hard. This project concerns a possible way of getting the right gene into a sick person's chromosome. Some viruses that infect bacteria (called bacteriophages or phages) have a way of getting their own genes into the chromosome of their bacterial hosts. This process involves proteins called integrases, because they integrate two pieces of DNA into one. Most integrases use a particular site, an attB site, in the bacterial chromosome preferentially over all others and the phage DNA goes into that site. There is also a preferred site in the phage DNA, the attP site. In order to introduce correct genes into people as a cure for disease, we need to engineer the integrase so that it can find a safe and suitable site for integrating DNA in that person's chromosome. Consequently this project is about understanding how these integrases work so that we can alter them in a rational way. We would like to know, for instance, how integrase is controlled. A feature of integrase is that it is irreversible in the absence of any other phage proteins. This means that once the correct gene is inserted it is there forever, hence the need for only one treatment. In fact what we mean by irreversible is that it can only use the attP and attB sites in the integration reaction. During this process the two halves of attP get split and join up with the two halves of attB site to form hybrid sites attL and attR. Of these four sites integrase only reacts with attP and attB. Integrase detects the presence of attP and attB very early on in the reaction pathway, a stage that brings the two sites together. There is a kind of lock and key interaction between integrases bound to the two sites attP and attB that activates the rest of the pathway to complete integration. Without the right lock and key interaction, such as when integrase is bound to two attP sites, an attP and an attL site or the attL and attR sites, the pathway is blocked. We have recently discovered a small part of integrase, a 'control module', that is part of a mechanism that senses which type of site it is bound to and communicates this information to generate a 'lock' or a 'key' type structure. We have discovered that a truncated integrase (the C-terminal domain or CTD) that lacks the part of integrase necessary for the chemistry of the reaction, but still contains the control module and DNA binding activity, can do the lock and key reaction on its own. We have broken down integrase still further to just the control module which we showed can bind to itself. Is this the lock and key interaction that occurs in full length integrase? We will use more mutants to test ideas about how the control module interacts with itself and whether this is the lock and key interaction or whether it is part of a sensing mechanism that discriminates between attP and attB on DNA binding. We will also try to identify the part of integrase that directly recognises the attP and attB sites and how this interacts with the control module. Finally we will look at the very beginning of the integration reaction, i.e. the process of DNA binding, and use chemicals and thermodynamics to look at how the footprints made by integrase on the attP and attB sites are different.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/cbic.201300037
发表时间: 2013-03-18
期刊: CHEMBIOCHEM
影响因子: 3.2
作者: [Koehnke, Jesko, Morawitz, Falk, Bent, Andrew F., Houssen, Wael E., Shirran, Sally L., Fuszard, Matthew A., Smellie, Iain A., Botting, Catherine H., Smith, Margaret C. M., Jaspars, Marcel, Naismith, James H.]
通讯作者: Naismith, James H.
DOI: 10.1093/nar/gkt1101
发表时间: 2014-02
期刊: Nucleic acids research
影响因子: 14.9
作者: [Colloms SD, Merrick CA, Olorunniji FJ, Stark WM, Smith MC, Osbourn A, Keasling JD, Rosser SJ]
通讯作者: Rosser SJ
DOI: 10.1107/s1744309113012931
发表时间: 2013-06
期刊: Acta crystallographica. Section F, Structural biology and crystallization communications
影响因子: --
作者: [Bent AF, Koehnke J, Houssen WE, Smith MC, Jaspars M, Naismith JH]
通讯作者: Naismith JH
DOI: 10.1038/nsmb.2340
发表时间: 2012-08
期刊: NATURE STRUCTURAL & MOLECULAR BIOLOGY
影响因子: 16.8
作者: [Koehnke, Jesko, Bent, Andrew, Houssen, Wael E., Zollman, David, Morawitz, Falk, Shirran, Sally, Vendome, Jeremie, Nneoyiegbe, Ada F., Trembleau, Laurent, Botting, Catherine H., Smith, Margaret C. M., Jaspars, Marcel, Naismith, James H.]
通讯作者: Naismith, James H.
SBIR Phase I: A language learning app based on sound and mouth movements
  • 批准号:
    2323040
  • 项目类别:
    Standard Grant
  • 资助金额:
    $27.47万
  • 财政年份:
    2023
  • 负责人:
    Margaret Smith
  • 依托单位:
TARGeTED: Tackling Antimicrobial Resistance through Goal-orientated Thinking in the EPS Disciplines
  • 批准号:
    EP/M027538/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $51.34万
  • 财政年份:
    2015
  • 负责人:
    Margaret Smith
  • 依托单位:
Novel industrial bioprocesses for production of key valuable steroid precursors from phytosterols
  • 批准号:
    BB/L003619/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $39.79万
  • 财政年份:
    2013
  • 负责人:
    Margaret Smith
  • 依托单位:
Overcoming antibiotic resistance by studying antibiotic hypersensitivity
  • 批准号:
    BB/J016691/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $69.6万
  • 财政年份:
    2012
  • 负责人:
    Margaret Smith
  • 依托单位:
国内基金
海外基金
噬菌体phiC31整合酶在牛基因组中介导基因定点整合的分子机制研究
  • 批准号:
    31301009
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2013
  • 负责人:
    曲立娟
  • 依托单位:
联合应用phiC31整合酶与微环载体对β654地中海贫血小鼠进行基因治疗
  • 批准号:
    81300449
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2013
  • 负责人:
    周在威
  • 依托单位:
基于ZFN/phiC31系统的新型基因打靶技术的建立(果蝇)
  • 批准号:
    31171278
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2011
  • 负责人:
    高冠军
  • 依托单位: